In PAH, endothelial dysfunction results in reduced NO bioavailability, leading to impaired sGC activation and decreased cGMP levels, which contribute to increased pulmonary arterial pressure and vascular remodeling [45]. Here, SGCB is linked to pulmonary arterial hypertension.